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Abstract 
While deployment of intracoronary stents has been shown to reduce restenosis, stenting 
can also damage the endothelial monolayer lining the vessel wall, leading to possible in-
stent thrombosis. Local drug delivery from stent surfaces represents a means of delivering 
therapeutic doses of drug directly to the target site. The aim of this study was to elute 
fluvastatin, which can inhibit vascular smooth muscle cell proliferation, and xemilofiban, 
which prevents platelet adhesion and aggregation, together in bioactive concentrations 
from the same copolymer system. Combined elution from thermoresponsive N-
isopropylacrylamide (NiPAAm)/N-tert-butylacrylamide (NtBAAm)-derived copolymer 
systems was achieved using microgels (NiPAAm/NtBAAm 65/35 wt/wt) randomly 
dispersed in 85/15 matrices. Fluvastatin elution from 5 m films over a 14-day period 
showed initial burst release, which leveled off. Of the total incorporated (8.33 ± 0.21 
nmol, n=4), 68.5 % was eluted during this period.  Xemilofiban release was measured in 
terms of its ability to inhibit platelet adhesion, using a microfluidic system.  To 
investigate the influence of location and hydrophobicity on elution of bioactivity, three 
separate systems were employed. While elution of anti-adhesive activity from the system 
containing xemilofiban-loaded matrices was more dramatic in the short term, a more 
sustained level of inhibition was achieved when xemilofiban had been incorporated into 
microgels. All samples investigated for anti-adhesive activity also decreased human 
coronary artery smooth muscle cell proliferation. Therefore xemilofiban has potential as 
an agent for preventing in-stent thrombosis. Our study has demonstrated the feasibility of 
using this novel matrix/microgel system to regulate simultaneous release of both agents 
in bioactive concentrations. 
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INTRODUCTION 
 
  The use of intravascular coronary stents during angioplasty procedures was first 
reported by Ulrich Sigwart in 1986.
1
 With the utilization of a stent there is the possibility 
of increased neointimal hyperplasia, as the metallic stent can cause physical injury to the 
endothelium, which can result in in-stent restenosis (ISR) and in-stent thrombosis (IST). 
Those higher risk patients with complex lesions (small vessel, bifurcation lesions) have 
an in-stent restenosis (ISR) occurrence rate of 30 – 60 %, while in those with less 
complex lesions the rate is reduced to 15 – 20 % of patients.2 IST has an occurrence rate 
of ≈1 %.3  
  Drug-eluting stents (DES) have had a major influence on the reduction of in-stent 
restenosis. To prevent restenosis, a clear understanding of events responsible for growth 
factor- or cytokine-mediated vascular smooth muscle cell (VSMC) proliferation and 
migration (intimal hyperplasia) has led to a precise selection of potential therapeutic 
candidates.
4
 However, the current leading agents, sirolimus and paclitaxel, can inhibit 
endothelial cell as well as VSMC proliferation, thereby affecting the re-endothelialisation 
process which is central to vessel recovery. HMG CoA reductase inhibitors (statins) 
could be an option for the inhibition of neointimal hyperplasia, since these agents inhibit 
VSMC proliferation by a mechanism independent of cholesterol synthesis.
5 
  In an attempt to prevent the problem of IST, patients are placed on a strict regime of 
anti-platelet agents. However despite these adjunct therapies, stent thrombosis still occurs 
in 1% of patients.
6
 The residual occurrence of IST may be caused by lack of penetration 
of such agents in adequate concentrations to the desired site of action following oral or 
systemic administration. Local delivery of agents designed to inhibit VSMC proliferation 
and platelet aggregation via a copolymer-coated stent platform is an attractive strategy for 
offsetting the incidence of ISR and IST.  
Poly (n-isopropylacrylamide) (NiPAAm) is a polymer that can become inversely soluble 
upon heating. This change in state occurs at what is known as the lower critical solution 
temperature (LCST).
7
 Below the LCST the polymer chains are extended, separated and 
surrounded by water, but above the LCST the polymer becomes insoluble and 
precipitates out of solution.
8
 The temperature range at which the soluble-insoluble shift 
occurs in relation to NiPAAm is between 31-34ºC. The addition of N-tert-butyl-
acrylamide (NtBAAm) alters the relative hydrophobicity/hydrophilicity of NiPAAm 
thereby giving a means for regulating the elution of drugs for local delivery on the basis 
of their polarity. In this study, a range of copolymers exhibiting increasing 
hydrophobicities were synthesised in varying (w/w) ratios of NiPAAm/NtBAAm (85/15, 
65/35 and 50/50).   
 The potential of NiPAAm/NtBAAm-derived copolymers to act as drug delivery vehicles 
for small molecules like colchicine
9-10
 and therapeutic proteins like vascular endothelial 
growth factor (VEGF)
11
 has been previously investigated. Another approach is to cross-
link NiPAAm/NtBAAm copolymer microgel particles and disperse these through a bulk 
copolymer matrix. At their LCST the network volume changes from an expanded water-
containing network, to a collapsed network where the water has been expelled. As the 
temperature increases the particles shrink and become hard and sphere shaped.
12
 These 
microgels are then dispersed through the non cross-linked NiPAAm/NtBAAm matrices 
and can be used for drug loading and elution. Our group has previously shown that 
fluvastatin could be eluted from these matrix/microgel copolymer systems for up to 60 
days with retention of bioactivity. 
 In this study, dual drug release from 3 different systems was investigated. System A was 
comprised 65/35 microgels containing fluvastatin embedded in a 50/50 matrix containing 
xemilofiban, while System B comprised 65/35 microgels containing fluvastatin 
embedded in an 85/15 matrix containing xemilofiban. Finally, System C contained 65/35 
microgels incorporating xemilofiban, embedded in an 85/15 copolymer containing 
fluvastatin. Bioactivity of fluvastatin was assessed in terms of effects on human coronary 
artery smooth muscle cell (HCASMC) and human coronary artery endothelial cell 
(HCAEC) proliferation while the bioactivity of xemilofiban was evaluated in terms of 
effects on platelet adhesion under conditions of flow.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
Materials 
 
  N-isopropylacrylamide (NiPAAm; Acros Organics, USA) and N-tert-butylacrylamide 
(NtBAAm; Fluka, Switzerland) were recrystallized twice from n-hexane and dried at room 
temperature under vacuum.  N, N-Azobisisobutyronitrile (AIBN; Phase Separation, UK) was 
recrystallized from methanol. Solvents were reagent grade and were purified by conventional 
methods. 14C-fluvastatin (specific activity 56.9 Ci/mmol) was generously donated by 
Novartis, Hanover. Xemilofiban (SC-54701) was kindly donated by Dr. Dermot Cox, RCSI. 
HCASMC with the corresponding growth medium (Medium 231) were purchased from 
Cascade Biologics (Belgium). HCAEC with the corresponding medium (Endothelial Cell 
Growth Medium) were purchased from Promocell. 5-Bromo-2’-deoxyuridine (BrdU) was 
obtained from Roche Diagnostics (Germany). All other chemicals and reagents were of the 
highest grade commercially available. 
 
Preparation of NiPAAm/NtBAAm copolymers 
 
  The copolymers were synthesized through free radical polymerisation of the 
corresponding monomers with AIBN used as an initiator. The methodology was as 
outlined by McGillicuddy et al.
13
  Briefly, mixtures of NiPAAm and NtBAAm 
monomers in different ratios were dissolved in benzene with AIBN then added. The 
removal of oxygen was achieved by bubbling N2 gas through the solution for 30 min. 
Polymerisation then proceeded at 60°C for 24 h. Benzene was evaporated off and the 
copolymer was dissolved in acetone and precipitated in n-hexane. This whole procedure 
was repeated three times. The purified copolymer was dried at room temperature under 
vacuum. 
Preparation of microgels 
 
  Microgels were synthesized using the method of dispersion polymerisation.
14
 In their 
desired w/w ratios (85/15, 65/35, 50/50, total 0.2 g) NiPAAm/NtBAAm and 
bisacrylamide (0.02g) were dissolved in 36 ml of water. One ml of 0.1 wt % Triton 
solution was added and heated to 70°C. The solution was degassed by bubbling with N2. 
Ammonium persulphate (0.02g) was dissolved in 4 ml of water, degassed, and added 
slowly to the stirring monomer solution, under an atmosphere of N2. The reaction was left 
for 12 h at 70°C and the resulting microgel dispersion (1 wt % in water) cleaned by 
dialysis, and freeze-dried before use. 
 
Preparation of, and drug incorporation into matrix/microgel copolymer systems 
 
  Fluvastatin was incorporated into 65/35 microgel particles (5 mg) by incubation with 1 
mL of an ethanolic solution of 5mM drug containing tracer levels of [
14
C]-fluvastatin for 
24 h at 4˚C. The microgel/drug suspension was then centrifuged at 5000 rpm for 10 min, 
the supernatant containing unincorporated drug was removed, and the microgels 
resuspended in 0.5 ml ethanol. Drug-loaded microgel suspensions were subsequently 
added to 0.5 mL of a 10% 50/50 or 85/15 matrix copolymer solution containing 2.5mM 
xemilofiban. Alternatively xemilofiban was incorporated into 65/35 microgel particles 
which were subsequently incorporated into a 50/50 matrix containing fluvastatin. 
Aliquots (27 µl) of the resulting suspensions were applied evenly to the wells of 24-well 
tissue culture plates and were allowed to dry overnight in an ethanolic atmosphere. 
 
 
 
  
Drug release from copolymer films 
 
  Dried films were washed with prewarmed PBS (37˚C) to retain the collapsed state of the 
copolymer, prevent its dissolution, and remove any surface-bound drug. Drug elution 
from the resulting films at 37°C was monitored (as [
14
C]-fluvastatin) every 24 h by 
removing, storing and replacing the PBS solution. The amount of [
14
C]-fluvastatin eluted 
into the overlying solution was determined by scintillation counting against a suitable 
standard curve, from which total eluted fluvastatin was determined. 
 
Cell culture 
 
  HCASMC that had been isolated from a 21-year old Caucasian male by Cascade 
Biologics were received as cryopreserved cultures (passage 2) from Cytotech Ltd. 
(Denmark). The cells were maintained in their appropriate medium, Medium 231, 
supplemented with foetal bovine serum (4.9%), basic fibroblast growth factor (2ng/ml), 
epidermal growth factor (0.5g/ml), heparin (5ng/ml), insulin (5µg/ml), BSA (0.2µg/ml), 
gentamicin (10µg/ml) and amphotericin B (0.25µg/ml). The cells were grown to 
confluency in 75cm
2
 filter top tissue culture flasks and were maintained at 37ºC in a 
humidified atmosphere containing 95% O2 and 5% CO2. Subcultures were created by 
passaging using a trypsin/EDTA (T/E) (0.025 %/0.01 %) mixture in phosphate buffer 
saline (PBS), harvested by centrifugation (3 min at 433 x g) and seeded at stated 
densities. Cells of passages 4-10 were used for experiments. 
  HCAEC were purchased from Promocell (Germany). The cryopreserved cells (passage 
2) received had been isolated from a 63-year old Caucasian male. The appropriate 
endothelial cell growth medium was used to maintain the HCAEC. The medium was 
supplemented with 20 % heat-inactivated foetal calf serum (FCS), endothelial cell growth 
supplement/heparin (2ml), human recombinant epidermal growth factor (5µg/500 µl), 
hydrocortisone (500µg/500µl), gentamicin (10µg/ml) and amphotericin B (0.25µg/ml). 
The cells were grown to confluency in 75cm
2
 filter top tissue culture flasks and were 
maintained at 37ºC in a humidified atmosphere containing 95% O2 and 5% CO2. 
Subcultures were created by passaging using a T/E (0.025 %/0.01 %) mixture in PBS, 
harvested by centrifugation (3 min at 433 x g) and seeded at stated densities. Cells of 
passages 4-10 were used for experiments. Cells were also routinely tested for the 
presence of mycoplasm. 
 
Measurement of cellular proliferation (BrdU ELISA) 
 
  HCASMC or HCAEC (3 x 10
4
 cells/ml/well) were seeded into 96-well plates and left to 
adhere overnight. Cells were then incubated with samples of fluvastatin eluted from the 
various copolymer systems and left for 48h. Proliferation was subsequently assessed by 
measurement of BrdU incorporation into the DNA of proliferating cells using a 
colorimetric ELISA. 
 
Measurement of platelet adhesion under conditions of flow 
 
  A novel microflow system consisting of a novel syringe pump with microfluidic biochip 
and flow sensor controlled by a PC using dedicated software was used to assess the 
effects of eluted samples of xemilofiban. Blood was collected from healthy volunteers 
who were not taking any medication and were free from aspirin and other anti-platelet 
agents within the previous 2 weeks. The blood was drawn by venupuncture into tubes 
containing a 1:10 volume of 3.8% (wt/vol) trisodium citrate and gently mixed.  Each 
microgel channel of the novel microflow system was coated overnight in humid 
conditions at 4°C with fibrinogen (2µg/ml). All channels were then coated with BSA 
(10µg/ml) to saturate non-specific binding sites and left for approximately 30 min. Prior 
to the shear experiments all channels were washed through with JNL. Aliquots of whole 
blood were incubated for 5 or 10 min with the day 1, 3, 9 and 14 samples released from 
the following copolymer films: 
A) 65/35 microgels containing fluvastatin embedded in a 50/50 matrix containing 
xemilofiban 
B) 65/35 microgels containing fluvastatin embedded in an 85/15 matrix containing 
xemilofiban 
C) 65/35 microgels containing xemilofiban embedded in an 85/15 copolymer containing 
fluvastatin. 
  Whole blood and sample were together infused into the fibrinogen-coated channels 
under a shear stress of 32 dyne cm
-2
 for 3 min. Images at the indicated shear stress levels 
were captured using MetaMorph imaging software for analysis at a later time. 
 
Data analysis 
 
  Data are presented as means ± SEM of the indicated number (n) of determinations. 
Statistical analysis of differences between groups was performed by ANOVA, followed 
by Bonferroni’s multiple comparisons post-test. The statistical package PRISM was used 
for all analyses. Differences between means were considered significant when p < 0.05. 
 
 
 
 
 
 
RESULTS 
Drug elution from copolymer films  
 
  For normalization purposes, all release data were graphed as a percentage of total drug 
incorporated into copolymer films. The elution of fluvastatin from fluvastatin-loaded 
65/35 microgels embedded in a xemilofiban-containing 85/15 matrix saw a release of 
12.69 ± 0.74 % on day 1 with a total release of 68.55 ± 1.54 % by the final day (Fig. 1A). 
After the 14-day elution a distribution graph was calculated to show the amounts eluted, 
remaining and total amount incorporated in the system (Fig. 1B).  A total of 8.33 ± 0.21 
nmol was incorporated, 5.71 ± 0.13 nmol were eluted and 2.58 ± 0.12 nmol remained 
upon completion. 
  
Effect of native and eluted xemilofiban on platelet adhesion as assessed using a 
microfluidic system 
 
  Xemilofiban had a statistically significant effect on platelet adhesion at concentrations 
of 0.01 and 0.1 µM, with adhesion being reduced to 56.06 ± 7.8 % and 3.44 ± 1.43 % of 
controls, respectively (Fig. 2).  
 A group of controls were used in the experiment with a “high” xemilofiban 
concentration (1µM), a “low” xemilofiban concentration (0.01µM) and a “low” 
concentration of fluvastatin (0.1µM). All samples were mixed with whole blood and 
subjected to shear. Of the controls the “high” xemilofiban concentration significantly 
inhibited platelet adhesion, reducing it to 5.81 ± 1.59 %. “Low” xemilofiban reduced 
platelet adhesion to 65.25 ± 9.91 % and “low” fluvastatin to 57.83 ± 19.13 %. The images 
from which these results were extrapolated also show clearly the decrease in platelet 
adhesion using the high xemilofiban concentration (Fig. 3). System A (the most 
hydrophilic system of the 3) showed significant decreases for day 1 and 3 with adhesion 
reduced to 7.18 ± 3.02 % and 15.46 ± 5.62 %, respectively; thereafter platelet adhesion 
increased to 62.43 ± 20.4 % and 82.08 ± 24.97 % respectively. System B (the more 
hydrophobic system) showed a significant decrease for day 1 with a reduction to 8.74 ± 
4.57 %. On days 3, 9 and 14, there was no significant difference in reductions; however 
there was an apparent reduction in platelet adhesion to half that of the control on day 14. 
Finally, with system C in which xemilofiban was incorporated into the microgels, there 
was a significant decrease seen for days 1, 3, 9 and 14, with reductions to 8.96 ± 5.14 %, 
47.97 ± 11.89 %, 50.54 ± 15.37 % and 51.11 ± 10.26 % respectively (Fig. 4). 
 
Effect of eluted fluvastatin on HCASMC proliferation  
 
  All samples eluted from each system significantly inhibited HCASMC proliferation 
(Fig. 5). It could be seen that while proliferation was inhibited in the presence of each 
sample, a steady loss in anti-proliferative activity was seen over time. Samples eluted 
from System A decreased proliferation to 12.86 ± 4.55 % of control, using the Day 1 
sample, with proliferation recovering to 62.29 ± 8.17 % by day 14. With regard to 
Systems B and C, proliferation was reduced to 8.17 ± 0.6 % and 8.32 ± 0.6 % of control 
respectively, on day 1. By day 14 HCASMC proliferation was 77.74 ± 9.44 % with 
System B, and 65.22 ± 7.69 % with System C. Upon comparison of anti-proliferative 
activity with that obtained with native fluvastatin, it can be approximated that fluvastatin 
was present in concentrations between 0.01 and 1.4 µM in samples tested from these 
systems.  
 
 
Effect of eluted fluvastatin on HCAEC proliferation 
 
  When endothelial cells were treated for 48h with the eluted samples, there was no 
statistically significant effect on proliferation seen in the presence of any sample from 
any of the 3 systems (Fig. 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
  The overall aim of this study was to control release and deliver bioactive concentrations 
of a HMG-CoA reductase inhibitor (fluvastatin) and glycoprotein IIb/IIIa antagonist 
(xemilofiban) from a NiPAAm/NtBAAm matrix/microgel drug delivery system. Using 
the thermoresponsive properties of the matrices and microgels, the potential of such 
systems for the elution of these drugs has been demonstrated. 
  The anti-proliferative nature of statins has been extensively studied. Statins have been 
reported to inhibit smooth muscle cell proliferation both in vitro and in vivo.
15
  
Lovastatin, simvastatin and cerivastatin were found to significantly inhibit VSMC 
proliferation when treated with concentrations of 0.1-50 µM.
16-17
 Takeda et al.
18
  found 
that simvastatin significantly inhibited cell proliferation in bronchial VSMC while having 
no effect on cell viability. An in vitro study by Corpataux et al.
19
 found that the reduction 
in smooth muscle cell proliferation produced by fluvastatin was significantly greater than 
that with other statins such as simvastatin, lovastatin, atorvastatin, cerivastatin and 
pravastatin. Jaschke et al.
17
 showed that after treatment with cerivastatin (0-100nM) only 
the highest concentration had a significant effect on endothelial cell proliferation. Thus, 
although fluvastatin was used to treat both HCAEC and HCASMC in this study, the latter 
were much more sensitive to these anti-proliferative effects. Therefore fluvastatin was 
selected as the statin of choice in the present project for local drug delivery due to its 
active and lipophilic nature, both essential requirements for a potential candidate for local 
drug delivery. 
 We have previously reported that NiPAAm/NtBAAm copolymers can elute fluvastatin 
for up to 60 days while retaining its bioactivity, as assessed under both static and 
perfusion conditions.
20
 The present study has further shown that it is possible to co-elute 
bioactive fluvastatin with a second drug type incorporated in the system. In System A 
fluvastatin was eluted from 65/35 microgels and then released through a hydrophilic 
85/15 matrix. While the inhibition of vSMC proliferation steadily decreased with each of 
the daily samples used, proliferation at 48 h was still inhibited. Samples eluted from the 
other two systems showed an inhibition of proliferation resembling that of System A.  
  In Systems A and B, fluvastatin was incorporated into the microgels and then eluted 
through hydrophilic (System A) or hydrophobic (System B) matrices. This may explain 
the slight differences between these systems i.e. System A samples showed slightly 
greater inhibiton of proliferation and the drug was eluted faster. With regard to System C 
fluvastatin was dispersed in the matrix and thus only had one barrier to pass through; the 
results here were similar to those for System A. This could be due to the fact that 
hydrophobic drug was eluted from microgels into a hydrophilic matrix in one instance 
and straight from a hydrophobic matrix in the other. It is possible that the time course of 
elution from a hydrophobic matrix is comparable to that of elution from microgels and a 
hydrophilic matrix together. However it is also important to note that major differences 
may only be seen with extension of the 14-day period (Fig. 6). The comparable levels of 
overall inhibition seen between systems could also be due to the fact that each of the 
systems is eluting a similar concentration of fluvastatin on the relevant days.  
  None of the samples eluted from system A-C had a significant effect on HCAEC 
proliferation after 48 h, which suggests that re-endothelialisation in vivo would not be 
impeded up to this point (Fig. 7). 
  The rationale for using the GpIIb/IIIa antagonist xemilofiban in this study was based on 
the fact that GpIIb/IIIa antagonists have been used successfully as intravenous anti-
platelet agents post-surgery (PTCA)
21
 following their development of oral agents, mixed 
results have been reported in their use in prevention of acute coronary syndromes and 
long-term management of patients.
22
 However with 5 large-scale trials completed by 
2001, which included over 42,000 patients (EXCITE,
23
 OPUS,
24
 SYMPHONY 1 and 2,
25-
26
 BRAVO
27
), it was consistently found that the GpIIb/IIIa agents xemilofiban, orbofiban, 
sibrafiban and lotrafiban were no more effective than aspirin when given post-surgery. 
However, another study showed that their use during PCA procedures was effective and 
in fact improved in-hospital survival rates.
28
 Heer et al.
29
 have also offered evidence of 
their effectiveness during primary angioplasty. Therefore their effectiveness as an 
intravenous treatment in conjunction with PCA gives an indication that these agents 
could be used for local delivery from a stent platform. 
  The rationale for elution of an anti-platelet agent has been strengthened by reports 
demonstrating elution of GpIIb/IIIa receptor monoclonal antibody from polymer-coated 
stents. Yin et al.
30
 showed that the GpIIb/IIIa receptor antibody eluted from I-PLA 
polymer-coated stents inhibited platelet aggregation. Aggarwal et al.
31
 showed that 
GpIIb/IIIa antibody could be eluted for up to 14 days, with antibody still remaining after 
that time under conditions of flow. 
  Our study firstly showed that xemilofiban concentrations of 0.01 and 0.1µM had a 
statistically significant effect on platelet adhesion (Fig. 3). This gives a good indication 
that xemilofiban is capable of exerting its effects under conditions of flow and that 
platelets in circulating blood are more susceptible to the anti-adhesive action of 
xemilofiban in this model. 
  Under conditions of flow System A showed that on day 1 and 3, samples decreased 
platelet adhesion significantly, and the results were in fact on a comparable level with the 
control “high xemilofiban” concentration; however day 9 and 14 samples had only a 
minor effect on adhesion equivalent to that of the “low xemilofiban” concentration (Fig. 
4 and 5). As this was a hydrophilic matrix it could be inferred that the hydrophobic 
xemilofiban was expelled rapidly and therefore only had a significant effect at day 1 and 
3. It may be possible to prolong the elution of the drug from this matrix type by 
incubating the matrix or microgels with a higher concentration of xemilofiban. 
Alternatively using a more hydrophobic matrix could also potentially prolong the release 
of xemilofiban. It should be noted here that measurement of the exact concentration of 
xemilofiban released was beyond the scope of the present study. 
  System B had 65/35 microgels containing fluvastatin embedded in a 50/50 matrix 
containing xemilofiban; this is the more hydrophobic system and therefore it could be 
anticipated that elution would be prolonged. With this system a statistically significant 
effect was seen on day 1 with a reduction to a level similar to “high xemilofiban”. This 
correlated well with the burst release that is usually seen on Day 1 with all systems. 
While the remaining samples did not elicit a statistically significant effect it could be seen 
that there was a trend towards continued inhibition of platelet adhesion (Fig. 5). Thus this 
system gave an indication that the inhibitory effect would have continued beyond 14 
days.  
  System C saw the incorporation of xemilofiban into 65/35 microgels, which were then 
embedded in a 50/50 matrix. This final system showed release of bioactive drug over an 
extended time interval. In this case drug would have firstly been released from the 
microgels and then passed through the hydrophobic matrix. Each of the daily samples had 
a significant effect on platelet adhesion, with the day 1 sample having the greatest effect 
(Fig. 5).   
     
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
  Overall, this study showed that it is possible to elute two bioactive drug types from one 
copolymer system, resulting in three points of information. Firstly alteration of the 
composition of the copolymer systems i.e. the hydrophobic or hydrophilic nature of the 
matrix or microgels can affect elution. Also placement in either matrix or microgels can 
alter the period of elution i.e. the incorporation of drug into the microgels can prolong the 
effect of the drug. The study finally shows that xemilofiban remains bioactive and can 
affect platelet adhesion under flow conditions. The use of thermoresponsive copolymers 
is relevant as they allow for the incorporation of drug into a soluble mixture followed by 
precipitation above the LCST onto, potentially, a stent. Therefore the thermoresponsive 
properties coupled with the relative hydrophobicities and hydrophilicities of the 
NiPAAm/NtBAAm copolymers adds to their potential for the delivery of numerous drugs 
for extended periods. Therefore this study has shown that two drugs eliciting different 
actions can be eluted for up to 14 days in bioactive concentrations with the potential for 
extended release. Also fluvastatin did not alter platelet adhesion at concentrations eluted 
nor did xemilofiban affect cell proliferation at estimated concentrations eluted. 
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Figure legends 
Figure 1: A) Cumulative release of fluvastatin from fluvastatin-loaded 65/35 microgels 
embedded in an 85/15 copolymer matrix containing xemilofiban over a 14-day period. 
The microgels were pre-incubated with 5mM fluvastatin while the matrix was pre-
incubated with 2.5mM xemilofiban and left overnight. Copolymer films were then cast in 
24-well plates and after 24 h PBS was added to the wells. On the final day the copolymer 
films were dissolved and total drug incorporated was calculated. Cumulative release was 
subsequently expressed as % of total drug incorporated into the films. Data are 
representative of mean ± S.E.M. of 4 individual copolymer films. B) Distribution graph 
of drug-eluting films releasing fluvastatin. The total amount of drug initially loaded into 
the copolymer films was determined after dissolving the copolymer films. Data are 
representative of mean ± S.E.M. of 4 individual copolymer films. 
 
Figure 2: Effect of xemilofiban on platelet adhesion as assessed using a microfluidic 
system. Whole blood which had been treated with increasing concentrations of 
xemilofiban was passed through microcapillary channels on a biochip under shear stress. 
Numbers of platelets adhered were counted using MetaMorph. Results were calculated as 
a % of control (no drug) and values are presented as mean ± S.E.M., n=3, ***p<0.001 
w.r.t. control.  
 
Figure 3: The effects of xemilofiban and fluvastatin on whole blood assessed using the 
microfluidic system. Whole blood was mixed with either drug and then passed through 
the fibrinogen coated biochannels and subjected to shear rate, images were captured using 
MetaMorph. Images are as follows: a) whole blood alone; b) high xemilofiban, 1µM; c) 
low xemilofiban, 0.01µM; d) fluvastatin 0.1µM.  
 
Figure 4: Effect of samples eluted from copolymer films on platelet adhesion assessed 
using the microfluidic system. System A composition was as follows 65/35 microgels 
containing fluvastatin embedded in a 85/15 matrix containing xemilofiban, System B was 
65/35 microgels containing fluvastatin embedded in an 85/15 matrix containing 
xemilofiban and System C was comprised of 65/35 microgels containing xemilofiban 
embedded in an 85/15 copolymer  containing fluvastatin Copolymer films were cast into 
24-well plates and overlaid with PBS and eluted samples were collected daily. Whole 
blood was treated with these eluted samples and passed through the microfluidic system. 
The amount of platelets adhered was counted using MetaMorph. Results were calculated 
as a % of control (no drug) and values are presented as mean ± S.E.M., n=5, ***p<0.001 
w.r.t. control.  
 
Figure 5: Effects of samples eluted from system A-C on HCASMC proliferation as 
assessed using the BrdU assay. Each sample was incubated with smooth muscle cells for 
48 h. Results were calculated as % of control (no drug) and values are presented as mean 
± S.E.M., n=3, ***p<0.001 w.r.t. control. 
 
 
Figure 6: Effects of samples eluted from system A-C on HCAEC proliferation as 
assessed using the BrdU assay. Each sample was incubated with endothelial cells for 48 
h. Results were calculated as % of control (no drug) and values are presented as mean ± 
S.E.M., n=3, N.S. w.r.t. control. 
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